VolitionRx's Nu.Q NETs Biomarker Shows Promise in Predicting Sepsis Outcomes

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed paper in Critical Care Medicine reporting that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. The study found significantly higher Nu.Q NETs H3.1 levels in septic shock patients compared to sepsis patients, and a dose-response relationship with acute kidney injury severity. These findings support the biomarker's potential use for risk stratification and early intervention in clinical settings.

The journal also published an independent editorial examining H3.1 nucleosomes as a potential marker of NET-mediated organ injury, further underscoring the scientific interest in this approach. Volition said the findings support ongoing commercial and licensing discussions for Nu.Q NETs, its nucleosome quantification technology designed to detect diseases associated with NETosis. The company believes the test could help clinicians anticipate disease progression, guide treatment decisions, and monitor patients over time across acute and chronic conditions.

Volition cited a total addressable market of $2.8 billion for the technology and said the latest findings add to previously published evidence supporting its potential clinical utility. Dr. Andrew Retter, Medical Consultant at Volition, commented: “Introducing Nu.Q NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors.”

The study's implications are significant given the high mortality and morbidity associated with sepsis, a condition that affects millions worldwide. Early identification of patients at higher risk of deterioration could enable more timely and targeted interventions, potentially improving outcomes and reducing healthcare costs. The biomarker's ability to predict the need for renal replacement therapy is particularly notable, as acute kidney injury is a common and serious complication in sepsis.

Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company's website at https://volition.com/.